Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Sound View Wealth Advisors Group LLC

Sound View Wealth Advisors Group LLC lowered its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 14.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,505 shares of the company’s stock after selling 2,152 shares during the quarter. Sound View Wealth Advisors Group LLC’s holdings in Kiniksa Pharmaceuticals International were worth $346,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in KNSA. US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $33,000. Wealthquest Corp acquired a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at $42,000. Robeco Institutional Asset Management B.V. purchased a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter worth $233,000. Pallas Capital Advisors LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter worth $236,000. Finally, Fox Run Management L.L.C. acquired a new position in Kiniksa Pharmaceuticals International during the first quarter worth $252,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Trading Up 2.9%

NASDAQ:KNSA opened at $39.50 on Tuesday. The company has a market cap of $2.99 billion, a P/E ratio of 87.78 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.82 and a twelve month high of $42.05. The company’s 50-day moving average price is $37.53 and its 200-day moving average price is $31.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). The business had revenue of $180.85 million for the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm’s revenue was up 61.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.18) EPS. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

KNSA has been the topic of several research analyst reports. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Wedbush reiterated an “outperform” rating and issued a $48.00 price objective (up from $44.00) on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, October 28th. Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company increased their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 50,490 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the transaction, the chief accounting officer owned 27,046 shares of the company’s stock, valued at approximately $1,051,278.02. The trade was a 65.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Sanj K. Patel sold 97,390 shares of the company’s stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total value of $3,781,653.70. Following the completion of the sale, the chief executive officer owned 111,794 shares of the company’s stock, valued at approximately $4,340,961.02. The trade was a 46.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 734,705 shares of company stock valued at $27,084,774. Insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.